30.49

6.80% 1.94

After Hours: 30.57 0.08 +0.26%

Viking Therapeutics Inc (VKTX)

Overview News Price History Option Chain Financials Why VKTX Down? Discussions Forecast

Viking Therapeutics Inc stock is traded at $30.49, with a volume of 8.58M. It is up +6.80% in the last 24 hours and down -4.00% over the past month. Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Previous Close:

$28.55

Open:

$33.745

24h Volume:

8.58M

Relative Volume:

2.70

Market Cap:

$3.45B

Revenue:

Net Income/Loss:

$-237.39M

P/E Ratio:

-14.39

EPS:

-2.1183

Net Cash Flow:

$-224.58M

1W Performance:

+15.98%

1M Performance:

-4.00%

6M Performance:

-23.51%

1Y Performance:

+3.99%

1-Day Range:

$30.18

$34.38

1-Week Range:

$26.89

$34.38

52-Week Range:

$18.92

$43.15

Viking Therapeutics Inc Stock (VKTX) Company Profile

Name

Viking Therapeutics Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

858-704-4660

Address

9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA

Employee

Twitter

@viking_vktx

Next Earnings Date

2025-10-22

Latest SEC Filings

VKTX's Discussions on Twitter

Compare VKTX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VKTX Viking Therapeutics Inc	30.49	3.23B	0	-237.39M	-224.58M	-2.1183
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-29-25	Initiated	Canaccord Genuity	Buy
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight
Apr-08-25	Initiated	Goldman	Neutral
Feb-13-25	Initiated	Scotiabank	Sector Outperform
Feb-07-25	Initiated	Citigroup	Neutral
Dec-02-24	Initiated	Piper Sandler	Overweight
Nov-22-24	Initiated	B. Riley Securities	Buy
Nov-04-24	Reiterated	H.C. Wainwright	Buy
Sep-11-24	Initiated	JP Morgan	Overweight
Jun-27-24	Initiated	Morgan Stanley	Overweight
May-16-24	Upgrade	Raymond James	Outperform → Strong Buy
Mar-26-24	Reiterated	Oppenheimer	Outperform
Mar-07-24	Initiated	Jefferies	Buy
Feb-28-24	Reiterated	Oppenheimer	Outperform
May-31-23	Resumed	ROTH MKM	Buy
Mar-28-23	Reiterated	Maxim Group	Buy
Mar-17-23	Initiated	Stifel	Buy
Jul-29-21	Resumed	BTIG Research	Buy
May-25-21	Downgrade	Raymond James	Strong Buy → Outperform
Jun-05-20	Initiated	BMO Capital Markets	Outperform
May-05-20	Initiated	Chardan Capital Markets	Buy
May-01-20	Initiated	BTIG Research	Buy
Jul-16-19	Initiated	Oppenheimer	Outperform
Jun-25-19	Initiated	Stifel	Buy
Mar-29-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Mar-14-19	Reiterated	Maxim Group	Buy
Feb-22-19	Initiated	SVB Leerink	Mkt Perform
Dec-12-18	Initiated	B. Riley FBR	Buy
Nov-19-18	Upgrade	Raymond James	Outperform → Strong Buy
Sep-18-18	Reiterated	H.C. Wainwright	Buy
Sep-18-18	Reiterated	Maxim Group	Buy
Sep-18-18	Reiterated	Raymond James	Outperform
Jul-20-18	Initiated	SunTrust	Buy
Jun-28-18	Initiated	Raymond James	Outperform
Jun-01-18	Reiterated	Laidlaw	Buy
May-31-18	Reiterated	Maxim Group	Buy
Mar-26-18	Resumed	H.C. Wainwright	Buy
Nov-28-17	Reiterated	Maxim Group	Buy
Nov-21-17	Initiated	ROTH Capital	Buy

View All

Viking Therapeutics Inc Stock (VKTX) Latest News

08:15 AM

Viking Therapeutics (VKTX) Valuation Check After Q4 2025 Earnings And Obesity Pipeline Progress - Yahoo Finance

08:15 AM

08:12 AM

Viking Therapeutics stock rating reiterated at Buy by Laidlaw - Investing.com Nigeria

08:12 AM

07:20 AM

Viking to push oral GLP-1/GIP drug into phase III obesity trial - BioWorld MedTech

12:00 PM

11:31 AM

Viking Therapeutics Stock Soars: What's Driving The Momentum? - Benzinga

11:31 AM

11:12 AM

Stock Movers: Equinix, Crocs, Viking Therapeutics - Bloomberg.com

11:12 AM

10:36 AM

Viking Therapeutics stock price target lowered to $118 by Raymond James By Investing.com - Investing.com Canada

10:36 AM

09:14 AM

Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Cuts Target Price to $99 - 富途牛牛

09:14 AM

08:41 AM

Viking Therapeutics (VKTX) Shares Rise on Promising Obesity Drug Updates - GuruFocus

08:41 AM

08:30 AM

Viking Therapeutics, Inc. (NASDAQ:VKTX) Q4 2025 Earnings Call Transcript - Insider Monkey

08:30 AM

08:03 AM

VKTX Posts Wider-Than-Expected Loss in Q4, Stock Up on Pipeline Updates - Yahoo Finance

08:03 AM

07:52 AM

Viking Therapeutics stock price target lowered to $118 by Raymond James - Investing.com

07:52 AM

07:23 AM

Viking Therapeutics rises after Q4 updates (VKTX:NASDAQ) - Seeking Alpha

07:23 AM

07:22 AM

Viking Therapeutics Advances Oral Obesity Drug Toward Final Clinical Trials - AD HOC NEWS

07:22 AM

07:07 AM

Morgan Stanley Trims Price Target on Viking Therapeutics to $99 From $102, Keeps Overweight Rating - marketscreener.com

07:07 AM

07:05 AM

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

07:05 AM

06:56 AM

Viking Therapeutics stock soars on plans for Phase 3 obesity drug trial - Investing.com

06:56 AM

05:51 AM

Viking Therapeutics stock (VKTX) slips premarket as Phase 3 obesity pill timeline comes into focus - Bez Kabli

05:51 AM

05:36 AM